New congressional bill would thwart patent thickets in order to speed generic drugs to market; GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

Taking stock of the drug industry, from the lab to the medicine chest

January 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | New congressional bill would thwart patent thickets in order to speed generic drugs to market The bill addresses the use of patent thickets by brand-name drugmakers to thwart would-be generic rivals from getting to market. By Ed Silverman GLP-1 drugs not linked to suicidal thoughts in FDA's early review Its preliminary analysis found no link but the agency will continue to review anecdotal reports about blockbusters like Ozempic and Zepbound. By Elaine Chen The highs — and lows — of JPM 2024 you should pay attention to 2024's JP Morgan Conference in San Francisco had it all: Novartis's Cytokinetics fling, Ailos Bio's comeup, and a milk pumping failure. By Damian Garde and Allison DeAngelis and Adam Feuerstein and Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser